Alexion Pharmaceuticals Inc

Alexion Pharmaceuticals — Merger or Acquisition (October 2019)

19 slides from Alexion Pharmaceuticals's merger presentation, Oct 21, 2019

  1. Slide 1: Rare Inspiration. Changing Lives.

    RARE INSPIRATION. CHANGING LIVES. Confidential – For internal use only

  2. Slide 2: In the Room - Bluebell

    IN THE ROOM - B L U E B E L L 2 | RARE INSPIRATION. CHANGING LIVES. John Orloff, MD Gianluca Pirozzi Camilo Garcia EVP SVP VP G l o b a l Hematology & R & D H R ROLE H e a d o f Nephrology L e a d R&D R&D TA Head T I M E W I T H 2 Y e a r s 2 Y e a r s ALEXION 3 W e e k s Confidential – For internal

  3. Slide 3: In the Room - New Haven

    IN THE ROOM – N E W H A V E N 3 | RARE INSPIRATION. CHANGING LIVES. Aradhana Sarin, MD Sharon Barr Rachael Alford EVP VP VP H e a d o f Chief Strategy G l o b a l and Business H e a d o f ROLE P r o d u c t O f f i c e r R e s e a r c h Development T I M E W I T H 2 Y e a r s 1 5 Y e a r s ALEXION 6

  4. Slide 4: Alexion to Acquire Achillion: Strategic Rationale

    ALEXION TO ACQUIRE ACHILLION 4 | RARE INSPIRATION. CHANGING LIVES. Strategic Rationale ✓ Opportunity to diversify into additional complement-mediated diseases using oral therapies • Adds clinical-stage portfolio of oral small molecule Factor D inhibitors to Alexion pipeline ✓ Potential to enhance tr

  5. Slide 5: Alexion by the Numbers

    ALEXION BY THE NUMBERS 5 | RARE INSPIRATION. CHANGING LIVES. 3000+ TALENTED COLLEAGUES AROUND THE GLOBE PRIX3 GALIEN AWARDS 20+ YEARS OF LEADERSHIP IN COMPLEMENT BIOLOGY APPROVED $4.75 4 DEVASTATING6 THERAPIES RARE DISEASES -4.8b SERVING PATIENTS IN Projected Revenues in 2019 50 (Per 2Q19 Earnings r

  6. Slide 6: Our 25+ Year Journey

    OUR 25+ YEAR JOURNEY 6 | RARE INSPIRATION. CHANGING LIVES. 1992 2015 2017 2018 Alexion founded in New Haven, CT STRENSIQ® (asfotase alfa) first approved Partnered with Halozyme Therapeutics and ULTOMIRIS® (ravulizumab-cwvz) first ® for the treatment of patients with HPP established license agreement

  7. Slide 7: Management Team

    MANAGEMENT TEAM 7 | RARE INSPIRATION. CHANGING LIVES. Ludwig Hantson, PhD Ellen Chiniara, JD Paul Clancy Indrani Franchini, JD Brian Goff Chief Executive Officer EVP, General Counsel EVP, Chief Financial Officer EVP, Chief Compliance Officer EVP, Chief Commercial Officer Anne-Marie Law John Orloff,

  8. Slide 8: Improving Patient Lives in More Than 50 Countries

    IMPROVING PATIENT LIVES IN MORE THAN 50 COUNTRIES 8 | RARE INSPIRATION. CHANGING LIVES. REGIONS OF OPERATION United States International Japan Partners Confidential – For internal use only Major offices in Boston, New Haven, Dublin, Zurich and Tokyo

  9. Slide 9: Our Values

    O U R V A L U E S 9 | RARE INSPIRATION. CHANGING LIVES. Our culture is rooted in integrity, inclusiveness, Serve Act with and our dedication to Patients Integrity joining and supporting the communities in which Empower Innovate for we live and work. People Solutions Confidential – For internal use o

  10. Slide 10: The Most Rewarding Company to Work For

    THE MOST REWARDING COMPANY TO WORK FOR 10 | RARE INSPIRATION. CHANGING LIVES. WORLD CLASS LEADERSHIP AND INNOVATION CAPABILITY Leaders cultivate the climate for innovation and connect us to the experience of those we serve Alexion delivers world-class innovation to patients and caregivers to help th

  11. Slide 11: Serving the Communities Where We Live and Work

    SERVING THE COMMUNITIES WHERE WE LIVE AND WORK 11 | RARE INSPIRATION. CHANGING LIVES. 85+ PROJECTS 20+ COUNTRIES Our Global Day of Service is an annual opportunity for 8,500+ us to make a positive impact VOLUNTEER HOURS on the lives of the people in our local communities and each 1,700+ other EMPLOY

  12. Slide 12: Our Key Areas of Focus

    OUR KEY AREAS OF FOCUS 12 | RARE INSPIRATION. CHANGING LIVES. EXPAND ULTOMIRIS® (RAVULIZUMAB-CWVZ) 1. IN PNH PATIENTS AND PREPARE FOR AHUS VISION LAUNCHES ACCELERATE NEUROLOGY AS KEY 2. GROWTH DRIVER WITH gMG AND NMOSD 2025 4 GROWING, DURABLE EXECUTE AND EXPAND CLINICAL STAGE FRANCHISES PIPELINE 3.

  13. Slide 13: Our Medicines

    OUR MEDICINES 13 | RARE INSPIRATION. CHANGING LIVES. ULTOMIRIS® SOLIRIS® STRENSIQ® KANUMA® (RAVULIZUMAB-CWVZ) (ECULIZUMAB) (ASFOTASE ALFA) (SEBELIPASE ALFA) FOR FOR FOR FOR PNH PNH HPP LAL-D aHUS aHUS gMG NMOSD Confidential – For internal use only

  14. Slide 14: 2017 Pipeline

    2017 PIPELINE 14 | RARE INSPIRATION. CHANGING LIVES. 5 Development Preclinical Early Clinical Advanced Clinical Registration Programs Internal Complement ULTOMIRIS QW SC ALXN1210 IV PNH eculizumab gMG Programs Other Research ALXN1210 IV aHUS eculizumab NMOSD Hematology & Nephrology Metabolics Neurol

  15. Slide 15: Achillion Bolsters Alexion's Early and Advanced Clinical Pipelines

    ACHILLION BOLSTERS ALEXION’S EARLY AND ADVANCED CLINICAL PIPELINES 15 | RARE INSPIRATION. CHANGING LIVES. 23 Development Preclinical Early Clinical Advanced Clinical Programs Planned Internal Complement ALXN1810 SC ALXN1840 (WTX101) ULTOMIRIS ALXN1210 QW SubQ Programs (ULTOMIRIS/PH20) Wilson Disease

  16. Slide 16: R&D Hiring to Deliver the Portfolio

    R&D HIRING TO DELIVER THE PORTFOLIO 16 | RARE INSPIRATION. CHANGING LIVES. +293 ~1200 R&D COLLEAGUES ADDED OR POSITIONS OFFERED YTD 2019 R&D COLLEAGUES AROUND THE GLOBE BY THE END OF 2020 PLAN TO HIRE UP TO …. +~175 from 2019 365 Yearend Headcount THIS YEAR IN TOTAL (pending budget approval) (+72 AD

  17. Slide 17: Acquisition Next Steps

    ACQUISITION NEXT STEPS 17 | RARE INSPIRATION. CHANGING LIVES. • Alexion’s acquisition of Achillion is subject to: • The approval of Achillion shareholders • Satisfaction of other customary closing conditions • Approval from relevant regulatory agencies, including clearance under the Hart-Scott Rodin

  18. Slide 18: Questions?

    18 | RARE INSPIRATION. CHANGING LIVES. QUESTIONS? Confidential – For internal use only

  19. Slide 19: Additional Information About the Proposed Transaction and Where to Find It

    ADDITIONAL INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT 19 | RARE INSPIRATION. CHANGING LIVES. • This document does not constitute a solicitation of any vote or approval. In connection with the proposed acquisition of Achillion by Alexion, Achillion intends to file with the SEC a

Alexion Pharmaceuticals — Merger or Acquisition (October 2019) on 6ix